Cepheid agrees to sell TB test at cost; biotech lab-space demand falls sharply

Taking stock of the drug industry, from the lab to the medicine chest

September 19, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

PRNewsFoto/Cepheid via AP STAT+ | After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost Doctors Without Borders called the price cut an "an important step," but criticized Danaher for not lowering the price on another cartrdige. By Ed Silverman STAT+ | Artificial wombs, after years in development, reach FDA review for human trials Extremely premature babies have limited medical NICU options. Could biobag artificial wombs be the answer? FDA begins investigation. By Lizzy Lawrence STAT+ | Biotech lab-space demand falls sharply as industry's 'sugar high' turns into a 'reset' Life science vacancy rates are the highest they've been in a decade, according to a report released by Jones Lang LaSalle. By Jonathan Wosen Chris Hondros/Getty Images Opinion: A popular breast cancer genomic test underestimates risks for Black women A commonly used 21-gene test underestimates the risks of breast cancer recurrence in Black women. That needs to change. By Nathalie McDowell Johnson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser